MediWound and Teva Amend Settlement Terms
Company Announcements

MediWound and Teva Amend Settlement Terms

Mediwound (MDWD) has released an update.

MediWound Ltd. and Teva Pharmaceutical Industries Ltd. have effectively agreed on a second amendment to their 2019 settlement agreement, which will resolve all outstanding issues related to their prior business relationship. This amendment includes a final payment of $4 million from MediWound to Teva, with conditions that include cash payment and setoff arrangements. The updated agreement reaffirms the full and final settlement of claims between the two parties and outlines the tax treatment for the payments.

For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.

Related Articles
Christine BrownMDWD Upcoming Earnings Report: What to Expect?
TheFlyMediWound announces Phase II study evaluating EscharEx
TheFlyMediWound files to sell 1.45M ordinary shares for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App